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Objective: Branched-chain amino acids (BCAAs) improve disorders of albumin 
metabolism, quality of life, subjective symptoms, and prognosis in patients with chronic 
hepatitis. However, it remains unclear whether they improve insulin resistance. We 
examined the effects of BCAAs on glucose tolerance and insulin sensitivity in patients 
with chronic hepatitis C and insulin resistance. Methods: Individuals with a definitive 
diagnosis of chronic hepatitis C and insulin resistance were eligible for participation. 
Eligible participants were randomly assigned to the BCAA group or a control group. 
Participants were then crossed over to the other treatment for a further 12 weeks. 
Baseline clinical features, laboratory markers, fatty acid levels, and insulin sensitivity, 
assessed with oral glucose tolerance tests and a hyperinsulinemic euglycemic clamp, 
were also examined before and 12 and 24 weeks after the beginning of the study. 
Results: Of the 27 patients who completed the study, 14 began in the BCAA group and 
13 began as controls. There were no significant differences in glucose metabolism 
parameters or lipid profiles between the groups. HbA1c values were improved in 10 
patients and worsened or remained unchanged in 17 patients. The only predictive 
variable for change in HbA1c was the baseline Matsuda index: the lower the index, the 
greater the improvement in HbA1c values. Conclusions: BCAA therapy did not have 
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adverse effects on glucose tolerance or insulin sensitivity in patients with chronic 
hepatitis C and insulin resistance. Moreover, it had a therapeutic effect on HbA1c 
values in patients with marked peripheral (primarily muscle) insulin resistance.  
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The liver is a key organ in glucose homeostasis and one of the major target organs of 
insulin. Insulin resistance increases in chronic liver disease [1] and is a risk factor for 
the progression of liver pathology, the development of hepatocellular carcinoma (HCC), 
and a decrease in long-term survival [1-3]. Therefore, insulin resistance is an important 
therapeutic target in patients at any stage of chronic liver disease. However, the use of 
pharmacological agents targeting to insulin resistance, such as biguanides and 
thiazolidinediones, is often limited in patients with advanced chronic hepatitis due to 
adverse effects, including lactic acidosis and severe hepatotoxicity. 
Branched-chain amino acid (BCAA) supplementation improves disorders of albumin 
metabolism, quality of life, subjective symptoms, and prognosis in patients with chronic 
hepatitis [4, 5]. It remains unclear whether BCAAs improve insulin resistance in 
humans. BCAAs have been reported to modulate glucose metabolism in in vivo studies 
[6-9]. In addition, they promote glucose uptake in skeletal muscle in a rat model of liver 
cirrhosis [6] and adipocytes from diabetic db/db mice [7] and reduce hepatic glucose 
production in insulin-resistant Zucker fa/fa rats [8]. In skeletal muscle isolated from 
non-diabetic rats [9], BCAAs promote glucose uptake by enhancing translocation of 
glucose the transporter 4 to the plasma membrane via phosphatidylinositol 3-kinase 
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(PI3K) and protein kinase C pathways independent of mammalian target of rapamycin 
(mTOR). However, BCAAs/amino acids up-regulate mTOR in hepatocytes and the 
cirrhotic liver [10, 11]. mTOR negatively regulates insulin-mediated PI3K activity by 
degrading insulin receptor substrates in skeletal muscle cells during long-term insulin 
treatment [12]. In addition, human metabolomic profiling has shown that plasma BCAA 
levels are higher in obese humans than in thinner individuals and are significantly 
correlated with insulin resistance [13]. Furthermore, recent large-scale metabolomic 
analyses have shown that plasma BCAA levels are highly significantly associated with 
future diabetes, especially in subjects with insulin resistance [14]. These findings 
suggest that BCAAs play a dual role in glucose metabolism in skeletal muscle, 
enhancing glucose uptake under normoinsulinemic conditions while causing insulin 
resistance under hyperinsulinemic conditions. In this regard, the effects of BCAA 
administration on glucose metabolism depend on the balance between insulin-dependent 
and -independent BCAA signaling pathways [6]. 
The present study examined the effects of BCAA therapy on glucose tolerance and 
insulin sensitivity in patients with chronic hepatitis C and insulin resistance using a 
glucose clamp technique and measuring changes in blood glucose levels after an oral 
glucose tolerance test (OGTT). This is the first randomized controlled clinical study to 
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A randomized, controlled, crossover trial of BCAAs in patients with chronic hepatitis C 
and insulin resistance was performed at Kanazawa University Hospital in accordance 
with the Declaration of Helsinki. The participants provided signed, written informed 
consent. This trial was registered with the University Hospital Medical Information 
Network (UMIN) Clinical Trials Registry (number UMIN000001093). 
 
Study protocol 
Individuals (aged 31–78 years) were recruited from outpatients at Kanazawa University 
Hospital. Those with a definitive diagnosis of hepatitis C virus-associated chronic 
hepatitis and insulin resistance, as determined by a level of fasting immunoreactive 
insulin (IRI) during the observation period ≥10 μU/mL, were eligible for participation. 
All drugs were allowed to be taken during the study. Patients were excluded from the 
study if they met any of the following criteria: 1) continuous serum albumin level ≤2.5 
g/dL; 2) regular treatment with an albumin preparation (at least once a week for 1 
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month or longer); 3) treatment with a BCAA preparation within 4 weeks prior to 
enrolling in the study; 4) coma of grade III or higher due to hepatic encephalopathy; 5) 
total bilirubin level ≥3.0 mg/dL; 6) concurrent hepatocellular carcinoma, as determined 
by diagnostic imaging; 7) alcoholic cirrhosis and alcohol dependence; 8) high-risk 
esophageal varices most likely requiring sclerotherapy in the near future; 9) concurrent 
renal failure most likely requiring dialysis in the near future; 10) congenital abnormality 
of BCAA metabolism; 11) poorly controlled diabetes with a fasting blood glucose level  
≥150 mg/dL, or diabetes treated with sulfonylureas, biguanides, thiazolidinediones, or 
insulin; 12) concomitant corticosteroid therapy; 13) concomitant interferon therapy; and 
14) inadequacy to participate in the study, as assessed by the investigators.  
 
Randomization 
Eligible participants were randomly assigned to the BCAA group or the control group. 
Those in the BCAA group were then prescribed oral supplementation with three packs 
of a BCAA nutrient (Livact (4.15 g/pack); Ajinomoto Pharma, Tokyo, Japan), taken 
three times a day: after breakfast, after dinner, and before sleep. The participants were 
then crossed over, without any washout, to the other treatment for a further 12 weeks. A 
random allocation sequence was computer-generated elsewhere. Neither the individuals 
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conducting the study nor the patients had access to the allocation sequence until the end 
of the study, when the final results were analyzed. The nutritional balance of the diet 
was monitored by a nationally registered dietitian. The composition of the diet of each 
patient was based on the following conditions: 30–35 kcal/kg per day total calories for 
ideal body weight (body mass index of 22), 1–1.5 g protein/kg per day, and a fat content 
equivalent to 25% of the total calories.  
Baseline clinical features, laboratory markers, and plasma amino acid and fatty acid 
profiles were also examined before and 12 and 24 weeks after the beginning of the 
study. Venous blood samples were obtained in the morning after an overnight fast.  
 
Evaluation of insulin sensitivity by OGTT 
After an overnight fast (10–12 h), a 75-g OGTT was performed at 8:30 a.m. Blood 
samples were obtained 0, 30, 60, 90, and 120 min after the glucose load for the 
measurement of plasma glucose and serum insulin concentrations. From the OGTT data, 
the Matsuda index, an index of whole-body insulin sensitivity (10,000/√ [fasting 
glucose × fasting insulin] × [mean glucose × mean insulin during OGTT]) that is highly 
correlated with the rate of whole-body glucose disposal during a euglycemic insulin 
clamp [15], was calculated. The homeostasis model assessment of insulin resistance 
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(HOMA-IR) was calculated using the formula HOMA-IR = (fasting insulin [μU/mL] × 
fasting plasma glucose [mg/dl]) / 405 [16]. The hepatic insulin resistance index (H-IR) 
was calculated as the product of the total areas under the curve (AUCs) for glucose and 
insulin during the first 30 min of the OGTT (glucose 0–30 [AUC] × insulin 0–30 
[AUC]). This index was strongly correlated with hepatic insulin resistance in a 
euglycemic insulin clamp study (fasting plasma insulin × basal endogenous glucose 
production) [17]. In any given individual, the HOMA-IR, H-IR (primarily liver), and 
Matsuda index (muscle plus liver) provide different information [15, 17]. 
 
Evaluation of insulin sensitivity through a hyperinsulinemic euglycemic clamp 
The insulin sensitivity of 11 of the 27 patients was also evaluated in a hyperinsulinemic 
euglycemic clamp study [18]. The patients did not receive any medication on the 
morning of the examination. At approximately 9 a.m., after an overnight fast of at least 
10 h, an intravenous catheter was placed in an antecubital vein in each subject for 
infusion, and a second catheter was placed in the contralateral hand for blood sampling. 
The euglycemic hyperinsulinemic clamp technique was performed using an artificial 
pancreas (model STG-22; Nikkiso, Tokyo, Japan), as described previously [19]. A 
solution of 0.8 U/mL insulin (Novolin R: Novo Nordisk, Copenhagen, Denmark) in 
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normal saline was allowed to remain in the intravenous lines for at least 15 min, and the 
lines were then flushed before starting the insulin infusion. Insulin was infused at a rate 
of 3.0 mU/kg/min, resulting in a steady-state insulin concentration of 290.3±61.7 
μU/mL (mean±SD). Blood glucose levels were continuously determined during the 
clamp study and maintained with a variable-rate infusion of 20% glucose at fasting 
levels or 100 mg/dL, whichever was higher. The steady-state period was maintained for 
30 min or longer, during which the coefficients of variation for blood glucose and the 
glucose infusion rate were each less than 5%. The glucose levels reached during the 
clamp study were 91.3±15.5 mg/dL. Insulin sensitivity was expressed as the glucose 
metabolic clearance rate (MCR) in mg/kg per minute. The mean MCR in healthy 
subjects (n=9; age, 26.6±2.9 years; body mass index [BMI], 22.3±2.1 kg/m2) was 
13.5±3.4 mg/kg/min [20]. 
 
Statistical analysis 
All of the data are expressed as the mean±standard error. The differences between the 
two groups were analyzed with a Mann-Whitney U test. We used the multilevel model, 
as recommended by Mills and colleagues for analyzing crossover studies [21]. This 
model was used specifically to allow for the assessment of whether there were any 
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effects with time or any carryover effect from one treatment phase to another. Therefore, 
3 months after a 3-month administration of BCAA are regarded as a washout period. To 
assess the treatment effect on the parametric data, these results were double checked 
with a paired t test after the exclusion of carryover effects [21]. Both the BCAA and 
control groups shared the baseline clinical characteristics of all of the subjects at the 
beginning of this study. Statistical comparisons between data from before the 
administration of the BCAAs and the data obtained after 12 and 24 weeks were 
performed using a Wilcoxon matched-pairs signed rank test. P-values of <0.05 were 
considered to be significant. 
 
Results 
Baseline metabolic parameters 
Figure 1 shows the trial profile and Table 1 shows the baseline characteristics of the 
participants. All of the patients were Japanese and lived in Ishikawa, Japan. The patients 
were recruited between March 2008 and March 2010, with follow-up continuing for 6 
months. Three participants withdrew before completion of the study. The first dropout 
case in the BCAA-first group, aged 63 years, voluntarily did not take the BCAA 
nutrient without any reasons and withdrew consent 1 day after the first treatment; the 
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second case in the control-first group, aged 55 years, declined to attend the study and 
withdrew consent 8 weeks after the first treatment started; and the third case in the 
control-first group, aged 59 years, did not attend the outpatient clinic 4 weeks after the 
first treatment started. Of the remaining 27 patients, 14 began in the BCAA group and 
13 began as controls. All of the patients who withdrew were excluded from the analysis 
because none of them completed their first course of treatment, and they only had 
baseline OGTT data. We performed a completed case analysis rather than an 
intention-to-treat analysis because there were few dropouts, and their reasons for 
dropping out were unrelated to baseline values or their response. No adverse effects of 
treatment were reported.  
There were no significant differences in any of the measured parameters between the 
groups before randomization, except for waist circumference and fasting plasma 
glucose (FPG). The BCAA-first group had a significantly lower mean waist 
circumference and a significantly lower mean FPG level than the BCAA-second group. 
For all of the subjects, the mean age was 61.3±2.1 years and the mean BMI was 
24.6±2.0 kg/m2. According to the inclusion criteria, all of the subjects were insulin 
resistant and the mean fasting IRI was as high as 18.4±4.0 IU/L. There were no 
abnormalities in the serum levels of total or direct bilirubin, alkaline phosphatase, total 
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protein, or creatinine in either group (data not shown).  
 
Effects of BCAAs on body composition and lipid, protein, and glucose metabolism 
The effects of administering BCAAs on body composition and lipid, protein, and 
glucose metabolism are summarized in Table 2. There were no significant differences 
between any of the glucose metabolism parameters (FPG, HbA1c, IRI, HOMA-IR, 
Matsuda index, H-IR, or MCR) or lipid profiles between the two groups. However, the 
BCAA group had significantly higher AST and ALT levels than the controls. The 
investigators were not given access to these results to maintain treatment blinding. The 
differences in the concentrations of hemoglobin, creatinine, and hepatic reserve were 
not significant between the two groups. These trends were similar in subgroups 
stratified by glucose tolerance (as diabetes, borderline glucose intolerance, and normal 
glucose tolerance) (Supplementary Table 1A-C). Additionally, unlike previous reports 
that suggested that BCAA-mediated improvements in insulin resistance are only 
observed in male patients [22, 23], there were no significant sex differences in the 
effects of BCAA in the present study (Supplementary Table 2A, B).  
 
Effects of BCAAs on amino acid metabolism  
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We measured plasma amino acid concentrations with high-performance liquid 
chromatography (HPLC)-electrospray ionization (ESI)-mass spectrometry (MS), 
followed by derivatization. An MSQ Plus LC/MS system (Thermo Fischer Scientific, 
Waltham, MA, USA) equipped with an ESI source was used in positive-ionization 
mode for selected ion monitoring (SIM). Xcalibur version 1.4 SR1 software (Thermo 
Fisher Scientific, Yokohama, Japan) was used for data collection and processing. The 
HPLC separation system consisted of an L-2100 pump, an L-2200 autosampler, and an 
L-2300 column oven (Hitachi High-Technologies Corporation, Tokyo, Japan). A 
Wakosil-II 3C8-100HG column (100, 2.1, 3 mm; Wako Pure Chemical Industries, 
Osaka, Japan) was used for separation, and the mobile phase consisted of eluent A (25 
mM ammonium formate in water, pH 6.0) and eluent B (water:acetonitrile=40:60).  
The plasma amino acid concentration profiles (aminograms) were analyzed for 
differences between the BCAA and control groups (Table 3). Remarkably, the 
component that showed the strongest difference between the groups was the 
combination of leucine, valine, phenylalanine, threonine, and proline (P<0.05). 
 




HbA1c values improved in 10 patients (37.0%), and worsened or remained unchanged 
in 17 patients (63.0%). As shown in Table 4, the only predictive variable for change in 
HbA1c was the baseline Matsuda index (P=0.014): the lower the index, the greater the 
improvement in HbA1c values. Furthermore, the rate of change of HbA1c tended to be 
correlated with the rate of change of the Matsuda index (r=-0.405, P=0.069). Other 
glucose metabolism markers, such as baseline IRI, HOMA-IR, H-IR, and MCR did not 
significantly predict changes in HbA1c values. 
 
Discussion 
Chronic liver disease, especially hepatitis C, is associated with insulin resistance and 
diabetes [1]. Indeed, liver disease is found in approximately 70% of patients with 
glucose intolerance and in approximately 40% of those with diabetes [24]. Conversely, 
diabetes and obesity affect the pathology of chronic liver diseases [25, 26]. We 
previously reported that diabetes and obesity accelerated histological prognosis, the 
development of liver cirrhosis and HCC, the recurrence of HCC after surgical treatment, 
and liver-related death in patients with hepatitis C [1-3]. Thus, insulin resistance is an 
important therapeutic target in patients with chronic hepatitis C of any stage. 
In the present open-label, randomized, controlled cross-over intervention trial, we 
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found that an increase in plasma levels of BCAAs after 12 weeks of oral administration 
of a BCAA preparation did not change the glycemic levels or insulin sensitivity in 
patients with chronic hepatitis C. However, when we stratified the patients regarding 
changes in glycemic control (HbA1c improved and non-improved), BCAAs improved 
glycemic control in patients with lower Matsuda index. Furthermore, the percentage 
change in HbA1c tended to be correlated with the percentage change in the Matsuda 
index (r=-0.405, P=0.069). However, serum IRI, H-IR, and HOMA-IR, which are 
thought to be hepatic insulin resistance indices, did not significantly predict changes in 
HbA1c values. BCAAs may only ameliorate glucose metabolism in patients with 
marked insulin resistance in the skeletal muscle. Therefore, contrary to our initial 
hypothesis, these findings suggest that BCAAs are effective in glycemic control in 
patients with type 2 diabetes, which is characterized by skeletal muscle insulin 
resistance.  
The limitations of our study include the short period of treatment of 12 weeks and the 
small numbers of patients investigated. To confirm the significance of BCAA therapy 
on insulin resistance in patients with chronic hepatitis C, a large-scale, long-term study 
is required to confirm our conclusion. 
In summary, BCAA supplementation therapy did not have adverse effects on glucose 
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tolerance or insulin sensitivity in patients with chronic hepatitis C or insulin resistance. 
BCAAs did not significantly improve overall glycemic control in the present study. 
However, notably, BCAA therapy may exert a beneficial effect on HbA1c values in 
patients with marked insulin resistance in the skeletal muscle. Currently, in Japan, 
BCAA supplementation is covered by insurance only for patients with chronic liver 
diseases. Based on our preliminary observations, future clinical trials should also 
evaluate the effect of BCAAs in patients with type 2 diabetes. 
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Figure 1. Trial profile and protocol. 
(1) Clinical features (including body composition) and laboratory markers. (2) 
Evaluation of insulin sensitivity based on OGTT results. (3) Evaluation of insulin 
sensitivity based on euglycemic insulin clamp results. 
Fig.1   Trial profile and protocol. (1) Clinical features (including body composition) and laboratory markers. (2) Evaluation of insulin 
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Table 1. Baseline characteristics of participants. 
All (N = 27) BCAA first (N = 14) Control first (N = 13) P value ･ 
Ages (years) 61.3 ± 2.1 58.6 ± 2.9 64.2 ± 3.0 N.S. 
Sex (Men Women) 8 : 19 5 : 9 3 :10 
Body Weight (kg) 60.1 ± 1.6 59.7 ± 2.2 60.5 ± 2.5 N.S. 
Waist circumference (cm) 87.9 ± 6.2 85.3 ± 1.6 90.9 ± 1.4 P = .016･ 
BMI (kg/m2) 24.6 ± 2.0 24.1 ± 0.5 25.0 ± 0.6 N.S. 
FPG (mg/dL) 96.2 ± 1.9 92.1 ± 2.1 100.6 ± 2.9 P = .025･ 
HbA1c (%) 4.9 ± 0.4 5.0 ± 0.1 4.9 ± 0.1 N.S. 
IRI (IU/L) 18.4 ± 4.0 13.8 ± 1.6 23.3 ± 8.0 N.S. 
HOMA-IR 4.6 ± 1.1 3.2 ± 0.4 6.1 ± 2.2 N.S. 
TC (mg/dL) 155.9 ± 7.9 159.1 ± 12.1 152.7 ± 10.6 N.S. 
TG (mg/dL) 84.3 ± 6.6 78.0 ± 8.4 90.5 ± 10.2 N.S. 
HDL-C (mg/dL) 47.5 ± 3.0 48.5 ± 5.4 46.5 ± 3.0 N.S. 
AST (IU/L) 53.3 ± 4.1 56.9 ± 6.9 49.4 ± 4.1 N.S. 
ALT (IU/L) 50.0 ± 7.1 57.4 ± 13.0 41.9 ± 4.4 N.S. 
BUN (mg/dL) 13.6 ± 0.8 12.6 ± 1.1 14.7 ± 1.3 N.S. 
HpT (%) 87.5 ± 4.3 89.4 ± 6.6 84.8 ± 4.8 N.S. 
Total protein (g/dL) 7.5 ± 0.1 7.6 ± 0.2 7.5 ± 0.2 N.S. 
Albumin (g/dL) 4.0 ± 0.1 4.1 ± 0.1 4.0 ± 0.1 N.S. 
BCAA (mmol/L) 412.5 ± 18.9 425.4 ± 29.7 398.5 ± 23.5 N.S. 
Matsuda index 3.0 ± 0.4 3.3 ± 0.7 2.7 ± 0.4 N.S. 
H-IR × 106 5.8 ± 0.5 6.1 ± 0.7 5.5 ± 0.7 N.S. 
 
All data are expressed as the mean and standard error. Differences between the two groups were analyzed by a 
Mann–Whitney U test. BMI, body mass index; FPG, fasting plasma glucose; IRI, immunoreactive insulin; 
HOMA-IR, homeostasis model assessment of insulin resistance; H-IR, hepatic insulin resistance index. 
 
■Difference between the BCAA-first group and the control-first group. P values of < .05 were considered 
significant. 
  
Table 2. Effects of BCAA on body composition, protein, lipid and glucose metabolism. 
BCAA group Control group P value ･
Body weight (kg) 61.1 ± 1.9 60.5 ± 1.9 N.S 
Waist circumference (cm) 87.8 ± 1.7 88.9 ± 1.7 N.S 
BMI (kg/m2) 24.9 ± 0.5 24.7 ± 0.4 N.S 
FPG (mg/dL) 96.6 ± 2.1 96.2 ± 2.0 N.S 
HbA1c (%) 4.9 ± 0.1 5.0 ± 0.1 N.S 
IRI (IU/L) 17.8 ± 3.6 21.2 ± 4.6 N.S 
HOMA-IR 4.5 ± 1.1 5.3 ± 1.3 N.S 
TC (mg/dL) 157.6 ± 7.2 164.9 ± 7.3 N.S 
TG (mg/dL) 78.3 ± 6.3 80.9 ± 5.3 N.S 
HDL-C (mg/dL) 49.4 ± 2.9 50.0 ± 2.7 N.S 
AST (IU/L) 61.2 ± 6.9 46.0 ± 3.0 P = .047･ 
ALT (IU/L) 68.3 ± 11.0 44.2 ± 4.8 P = .049･ 
BUN (mg/dL) 14.6 ± 1.0 12.9 ± 0.7 N.S 
HpT (%) 86.8 ± 4.2 91.4 ± 5.7 N.S 
Total protein (g/dL) 7.5 ± 0.1 7.6 ± 0.1 N.S 
Albumin (g/dL) 4.0 ± 0.1 4.0 ± 0.1 N.S 
BCAA (μmol/L) 472.6 ± 27.0 403.5 ± 21.0 P = .050･ 
Matsuda index 2.9 ± 0.3 2.5 ± 0.2 N.S 
H-IR × 106 6.6 ± 0.1 6.2 ± 0.6 N.S 
MCR (mg/kg/min) 9.8 ± 0.8 10.3 ± 1.0 N.S 
 
All data are expressed as the mean and standard error. Statistical comparisons between data from before 
administration of the BCAAs and data obtained after 12 and 24 weeks were performed using a Wilcoxon 
matched-pairs signed rank test. BMI, body mass index; FPG, fasting plasma glucose; IRI, immunoreactive 
insulin; HOMA-IR, homeostasis model assessment of insulin resistance; H-IR, hepatic insulin resistance 
index; MCR, glucose metabolic clearance rate. 
 
■Difference between the BCAA group and control group. P values of < .05 were considered significant. 
  
Table 3. Effects of BCAAs on amino acids metabolism. 
Baseline BCAA Control P value*
BCAA (μmol/L) 465.3 ± 99.4 461.4 ± 120.2 418.6 ± 99.6 N.S. 
Phenylalanine 103.7 ± 10.9 112.8 ± 23.9 105.5 ± 14.7 P = .014
Threonine 139.7 ± 26.1 121.3 ± 31.6 132.3 ± 28.4 P = .016
Proline 193.5 ± 59.7 172.8 ± 49.1 200.7 ± 86.0 P = .024
Leucine 140.3 ± 28.6 144.2 ± 40.8 129.5 ± 31.4 P = .025
Valine 253.9 ± 56.0 247.5 ± 61.8 219.7 ± 48.6 P = .040
Glycine 334.5 ± 46.2 306.6 ± 49.7 376.6 ± 272.5 N.S 
Tryptophan 64.9 ± 11.9 64.9 ± 13.9 62.2 ± 12.9 N.S 
Arginine 135.5 ± 31.9 125.9 ± 36.5 136.6 ± 37.5 N.S 
Ornithine 124.8 ± 27.2 114.0 ± 28.9 122.6 ± 37.1 N.S 
Isoleucine 71.2 ± 17.4 69.7 ± 21.4 69.3 ± 23.8 N.S 
Methionine 32.1 ± 11.5 35.5 ± 9.7 34.6 ± 7.5 N.S 
Glutamine 277.2 ± 169.5 365.2 ± 191.2 406.5 ± 157.4 N.S 
Lysine 20.8.7 ± 37.7 194.9 ± 41.2 193.3 ± 44.9 N.S 
Histidine 96.3 ± 10.7 92.7 ± 13.4 90.8 ± 12.3 N.S 
Citrulline 41.3 ± 11.9 40.9 ± 11.6 40.5 ± 11.1 N.S 
Asparagine 37.5 ± 10.4 43.2 ± 11.2 44.1 ± 7.4 N.S 
Alanine 485.5 ± 84.9 441.7 ± 78.5 463.4 ± 152.1 N.S 
Threonine 139.7 ± 26.1 121.3 ± 31.6 132.3 ± 28.4 N.S 
Tyrosine 131.5 ± 27.0 129.6 ± 24.9 130.3 ± 22.3 N.S 
 
All data are expressed as the mean and standard error. Statistical comparisons between data from before 
administration of the BCAAs and data obtained after 12 and 24 weeks were performed using a Wilcoxon 
matched-pairs signed rank test. 
 
■Difference between the BCAA group and control group. P values of < .05 were considered significant. 
  
Table 4. Baseline clinical features and laboratory markers associated with changes in HbA1c in 27 patients. 
HbA1c non-improved (N = 17) HbA1c improved (N = 10) P value ･
Body weight (kg) 61.6 ± 2.4 57.6 ± 2.2 N.S 
Waist circumference (cm) 87.7 ± 1.8 87.6 ± 1.5 N.S 
BMI (kg/m2) 24.7 ± 0.6 24.4 ± 0.3 N.S 
FPG (mg/dL) 97.6 ± 2.7 97.9 ± 3.1 N.S 
HbA1c (%) 4.9 ± 0.1 5.0 ± 0.1 N.S 
IRI (IU/L) 14.0 ± 1.6 29.0 ± 11.1 N.S 
HOMA-IR 3.5 ± 0.4 7.4 ± 3.1 N.S 
TC (mg/dL) 160.7 ± 11.4 146.8 ± 7.7 N.S 
TG (mg/dL) 91.6 ± 9.0 70.3 ± 7.2 N.S 
HDL-C (mg/dL) 48.8 ± 4.1 45.1 ± 4.0 N.S 
AST (IU/L) 49.1 ± 3.9 60.3 ± 8.7 N.S 
ALT (IU/L) 43.9 ± 5.1 60.2 ± 17.1 N.S 
BUN (mg/dL) 13.9 ± 1.1 13.1 ± 1.4 N.S 
HpT (%) 89.5 ± 6.5 84.1 ± 3.8 N.S 
Total protein (g/dL) 7.6 ± 0.2 7.4 ± 0.2 N.S 
Albumin (g/dL) 4.1 ± 0.1 3.9 ± 0.1 N.S 
BCAA (μmol/L) 412.3 ± 21.4 412.8 ± 40.0 N.S 
Matsuda index 2.9 ± 0.3 1.8 ± 0.2 P = .014･ 
H-IR × 106 5.5 ± 0.6 6.7 ± 1.0 N.S 
MCR (mg/kg/min) 10.1 ± 1.0 8.6 ± 1.3 N.S 
 
All data are expressed as the mean and standard error. Differences between the two groups were analyzed 
by a Mann–Whitney U test. BMI, body mass index; FPG, fasting plasma glucose; IRI, immunoreactive 
insulin; HOMA-IR, homeostasis model assessment of insulin resistance; H-IR, hepatic insulin resistance 
index ; MCR, glucose metabolic clearance rate. 
 
■Difference between the HbA1c-non-improved group and the HbA1c-improved group. P values of < .05 were 
considered significant. 
 
